Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice

Inclusion Criteria: * Any subjects who are previously using Actrapid®, Insulatard®, and Mixtard® 30 with vial / NovoLet® or insulin human with ErgoPen®2 for type 1 and type 2 diabetes treatment, will be eligible for the study after the physician has taken the decision to use study insulin products with the study devices Exclusion Criteria: * Subjects treated with Actrapid® Penfill®, Insulatard® Penfill®, or Mixtard® 30 Penfill® with NovoPen®3 or Actrapid® FlexPen®, Insulatard® FlexPen®, or Mixtard® 30 FlexPen® for more than 4 weeks before inclusion into this study * Subjects who were previously enrolled in this study * Subjects with a hypersensitivity to insulin human or to any of the excipients * Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months